Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01944969 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT01944969 is a Phase 3 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 26 participants.
The verdict
NCT01944969, a Phase 3 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)
Interventions
- DRUG Brexpiprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01944969
The ClinicalTrials.gov registry entry for NCT01944969 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Brexpiprazole is the first listed.
NCT01944969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01944969 about?
NCT01944969 is a clinical study titled "Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder". To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)
What is the current status of trial NCT01944969?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2013-10. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01944969?
The interventions under investigation include: Brexpiprazole (DRUG).
Who is sponsoring clinical trial NCT01944969?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.